echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Ann Intern Med: Influence of frailty on the efficacy and safety of dapagliflozin in heart failure patients with reduced ejection fraction

    Ann Intern Med: Influence of frailty on the efficacy and safety of dapagliflozin in heart failure patients with reduced ejection fraction

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Frailty may alter the risk-benefit profile of some treatments, and frail patients may have reduced tolerance to treatment


    prevention

    The study is a post hoc analysis of a phase 3 randomized clinical trial conducted at 410 sites in 20 countries (ClinicalTrials.


    Guidelines for Heart Failure Vascular

    Frailty index (FI) was calculated in 4742 of the 4744 randomly assigned DAPA-HF patients


    CONCLUSIONS: Dapagliflozin improved outcomes across all assessments, regardless of the patient's frail status


    CONCLUSIONS: Dapagliflozin improved outcomes across all assessments, regardless of the patient's frail status


    Original source:

    Jawad H.


    Jawad H.
    Butt, et al.
    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF Trial .
    Ann Intern Med 2022.
    https:// /10.
    7326/M21-4776 Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF

    Trial
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.